CCCC C4 Therapeutics Forward P/S Multiple

c4therapeutics.com (CCCC) - corporate logo

High drug toxicity risks and a dependence on external investments are weighing on the credit profile of C4 Therapeutics, Inc. (CCCC). On GURU.Markets, the forward P/S indicator demonstrates stable dynamics, with the metric currently standing at 11.10. Business resilience relies on the patent protection of the TORPEDO system and the diversified synthesis of molecules through partners in Massachusetts.

CCCC (c4therapeutics.com) Price to Expected Revenue Ratio history from 07/04/2022 to 11/15/2026

C4 Therapeutics - analytical breakdowns and key metrics (CCCC)

- current price and projected stock value:
Stock Price C4 Therapeutics Inc|CCCC - Analyst Target Range
- market capitalization data:
Market Capitalization C4 Therapeutics Corp|CCCC - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share C4 Therapeutics|CCCC - Total Net Assets|Market Capitalization to Book Value Ratio c4therapeutics.com|CCCC - Company Assets
- debt and liquidity data:
Total Debt to Capital C4 Therapeutics, Inc.|CCCC - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio C4 Therapeutics|CCCC - Aggregate Debt Obligations|Debt to Book Value C4 Therapeutics Corp|CCCC - Amount of Long-Term Liabilities|Company Short-Term Debts C4 Therapeutics|Quick Ratio c4therapeutics.com
- net income and valuation multiples indicators:
CCCC - Company Net Income|Expected Profit C4 Therapeutics, Inc.|CCCC - Company Value to Net Income|Forward P/E Multiple C4 Therapeutics Corp|CCCC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization C4 Therapeutics|CCCC - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months C4 Therapeutics|CCCC - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth c4therapeutics.com|CCCC - Net earnings per share growth this year|Projected earnings per share growth rate for next year C4 Therapeutics, Inc.
- issuer revenue and sales details:
CCCC - Company Sales|Company Future Revenue C4 Therapeutics Corp|CCCC - Market Cap to Revenue|Price to Expected Revenue Ratio C4 Therapeutics
Summary company analysis:C4 Therapeutics (CCCC)
Product sample of c4therapeutics.com

Advance payments from global pharma partners of C4 Therapeutics, Inc. (CCCC) directly impact the forward P/S ratio dynamics, reflecting market expectations for future revenue. This multiple compares current market capitalization with projected sales volume, allowing investors to assess the premium paid for protein degrader potential and timely recognize the risk of multiple compression during a trend correction.

Competing companies

Forward P/S Multiple GMAB (Genmab AS)|Projected Price to Revenue Exelixis Corp|Nuvalent Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kymera|IDYA (IDEAYA Biosciences) - Forward Price-to-Revenue Multiple|ELVN: Price to Expected Revenue Ratio|ORIC (oricpharma.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Relay Pharma RLAY|Forward P/S Multiple NRIX|Tyra Biosciences - Market Cap to Projected Revenue|Verastem - Forward Price-to-Revenue Multiple|Forward Price to Sales GLUE|CGEM: Forward Price-to-Revenue Multiple|Immuneering Inc. - Price to Expected Revenue Ratio|BDTX: Forward P/S Multiple|Repare Therapeutics - Forward Price to Sales|PMVP (PMV Pharmaceuticals, Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio karyopharm.com KPTI|Price-to-Projected Revenue Ratio Propanc Biopharma Inc. (PPCB)|BGMS (Cyclacel Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple AADI (Aadi Bioscience Inc)|Forward P/S Multiple Aileron Therapeutics ALRN|BPMC - Price-to-Projected Revenue Ratio|Future Price to Revenue GLYC|SWTX (springworkstx.com) - Forward Price-to-Revenue Multiple